Unknown

Dataset Information

Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial.


ABSTRACT:

Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has changed our lives. The scientific community has been investigating re-purposed treatments to prevent disease progression in coronavirus disease (COVID-19) patients.

Objective

To determine whether ivermectin treatment can prevent hospitalization in individuals with early COVID-19.

Design, setting and participants

A randomized, double-blind, placebo-controlled study was conducted in non-hospitalized individuals with COVID-19 in Corrientes, Argentina. Patients with SARS-CoV-2 positive nasal swabs were contacted within 48 h by telephone to invite them to participate. The trial randomized 501 patients between August 19th 2020 and February 22nd 2021.

Intervention

Patients were randomized to iv

SUBMITTER: Vallejos J 

PROVIDER: S-EPMC8250562 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature